Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $17.33

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given an average rating of “Hold” by the seven research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $17.86.

A number of brokerages have recently commented on YMAB. Canaccord Genuity Group boosted their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. HC Wainwright boosted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. BMO Capital Markets boosted their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Finally, Truist Financial assumed coverage on Y-mAbs Therapeutics in a research report on Friday. They issued a “buy” rating and a $21.00 price target for the company.

Y-mAbs Therapeutics Trading Down 2.0 %

NASDAQ:YMAB opened at $12.08 on Monday. The firm’s fifty day simple moving average is $13.07 and its 200 day simple moving average is $12.87. Y-mAbs Therapeutics has a twelve month low of $4.60 and a twelve month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $19.93 million during the quarter, compared to the consensus estimate of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. On average, analysts expect that Y-mAbs Therapeutics will post -0.45 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the transaction, the insider now owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Y-mAbs Therapeutics news, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the transaction, the chief financial officer now owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The disclosure for this sale can be found here. Insiders sold a total of 99,444 shares of company stock valued at $1,203,925 in the last quarter. 21.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in YMAB. Acadian Asset Management LLC increased its position in shares of Y-mAbs Therapeutics by 24.0% during the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after purchasing an additional 157,173 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Y-mAbs Therapeutics by 208.3% during the 3rd quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after purchasing an additional 92,765 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $562,000. Trexquant Investment LP increased its position in shares of Y-mAbs Therapeutics by 417.5% during the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock valued at $417,000 after purchasing an additional 61,785 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after acquiring an additional 52,610 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.